PDSB
PDS Biotechnology Corporation
NASDAQ · Healthcare · Biotechnology · US
$0.22
+0.00%Sep 4, 2026, 21:27 UTC
PDS Biotechnology Corp amended its $6,000,000 promissory note with YA II PN, Ltd., modifying payment and cure-period terms, including a mandatory deemed redemption of proceeds from non-ATM equity financings.
Aug 25, 2026, 00:00 UTC
PDS Biotechnology Corp terminated Stephan Toutain as Chief Operating Officer, effective August 21, 2026, with severance of twelve months' base salary and COBRA contributions.
Aug 19, 2026, 00:00 UTC
Lars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corp, effective September 12, 2026, and Janetta Trochimiuk was appointed interim Principal Accounting Officer effective the same date.
Aug 13, 2026, 00:00 UTC
PDS Biotechnology Corp reported a net loss of $9.8 million for Q2 2026, with a net loss per diluted share of $0.18, compared to a net loss of $9.4 million ($0.21 per share) in Q2 2025.
Jul 10, 2026, 20:35 UTC
PDS Biotechnology filed a prospectus to register the sale of up to 13.32 million shares of common stock by selling stockholders; the company will not receive any proceeds.
Source:Jun 15, 2026, 00:00 UTC
PDS Biotechnology Corp issued a $6,000,000 secured promissory note due 2027 to YA II PN, LTD., bearing 10% annual interest.